Retatrutide is a novel investigational peptide designed to act as a triple agonist of the GLP-1, GIP, and glucagon receptors. Early research suggests it may play a role in:

• Appetite regulation and weight management

• Glucose metabolism and insulin sensitivity

• Fat oxidation and energy expenditure

• Preservation of lean muscle mass during weight loss

RETA is currently being studied for its potential to outperform single or dual agonists in metabolic and obesity-related pathways.

Products are provided in lyophilized powder form and require reconstitution prior to use in research or laboratory testing.